"Insufficient financing has been a reason why breakthroughs [in antimicrobial R&D] are lacking...If the G7 members follow the lead of the UK and each commit to putting appropriately sized incentives into place, scientists around the world will have a real opportunity to create the kinds of drugs poised to save the lives of our children and our grandchildren," said John Alter during a U.S. Department of Health and Human Services (HHS)-hosted listening session. #AMR
Ryan Cirz
2mo
The UK scheme isn’t appropriately sized. Patients in the UK will be cut off from new antibiotics in the future as it becomes clear no one will bite at that bad math
Maybe the book title becomes: how a math problem becomes a global moral crisis!
Robert Horne
2mo
Makes all the sense in the world John - at some point, the G-7 countries need to make sure their health systems can support their populace. And we all know healthcare is hard to work without an ability to stave off infection.
In sufficient funding on research startups is the reason for this hectic activity.
One needs to recognize that to support innovation, US revenues matter the most because they come at the highest profit margin. We all know that antibiotics are a bargain to society but they aren’t priced that way. The best hope for the rest of the world will be if they are developed for the US market with value based payments to complete the investment-innovation cycle, and the rest of the world benefits. Fix insurance payments by reforming CMS payments for inpatient antibiotics thru DISARM or NTAP reform. To understand why this is so, read Tess Cameron’s excellent piece here: https://rapport.bio/all-stories/global-differential-pricing